SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15-20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is...

Descripción completa

Detalles Bibliográficos
Autores: Dómine Gómez, Manuel|||0000-0003-1634-9832, Moran Bueno, Teresa|||0000-0001-9172-0035, Isla, Dolores|||0000-0002-2483-198X, Martí, J.L., Sullivan, Ivana|||0000-0002-0434-3436, Provencio Pulla, Mariano|||0000-0001-6315-7919, Olmedo García, María Eugenia|||0000-0002-0643-493X, Ponce Aix, Santiago|||0000-0002-2289-4709, Blasco Cordellat, Ana|||0000-0001-5889-0382, Cobo, Manuel|||0000-0003-3402-1144
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:283561
Acceso en línea:https://ddd.uab.cat/record/283561
https://dx.doi.org/urn:doi:10.1007/s12094-020-02295-w
Access Level:acceso abierto
Palabra clave:Chemotherapy
Immunotherapy
Radiotherapy
SCLC
Descripción
Sumario:Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15-20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is the surgery followed by adjuvant therapy with platinum-etoposide. In stage IIB-IIIC, the recommended treatment is early concurrent chemotherapy with platinum-etoposide plus thoracic radiotherapy followed by prophylactic cranial irradiation in patients without progression. However, in the extensive stage, significant advances have been observed adding immunotherapy to platinum-etoposide chemotherapy to obtain a significant increase in overall survival, constituting the new recommended standard of care. In the second-line treatment, topotecan remains as the standard treatment. Reinduction with platinum-etoposide is the recommended regimen in patients with sensitive relapse (≥ 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary.

Similares en LA Referencia